首页 > 最新文献

Clinical and Investigative Medicine最新文献

英文 中文
Overview of the Canadian Clinician Investigator Trainees' Research Presented at the 2024 CSCI-CITAC Joint Meeting. 加拿大临床研究员实习生在2024年CSCI-CITAC联席会议上的研究综述
IF 1.2 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 DOI: 10.3138/CIM-47-4-REPORT
MohdWessam Al Jawhri, Salonee V Patel, Shubham Soni, Richard Huang, Robert X Lao

The 2024 Annual Joint Meeting (AJM) and Young Investigators' Forum of the Canadian Society for Clinical Investigation (CSCI) and Clinician Investigator Trainee Association of Canada (CITAC) was held on April 11, 2024, in Vancouver, British Columbia. Hosted in collaboration with the University of British Columbia (UBC) and the International Congress on Academic Medicine (ICAM), this meeting marked a significant opportunity for clinician investigator trainees to present their research and connect with national and international peers. The event included 70 trainees, consisting of 58 MD+ (MD/PhD, MD and PhD, MD-MSc, MD and MSc) and 12 Clinician Investigator Program and/or Surgeon-Scientist Training Program trainees. The keynote speaker, Dr. Marco Marra, delivered a presentation titled "From C. elegans Genetics to Precision Cancer Genomic Medicine, via the Human Genome Project: Reflections on a Collaborative Scientific Journey." Dr. Kenneth Rockwood (Dalhousie University) received the CSCI Distinguished Scientist Award, and Dr. Bertrand Routy (Université de Montréal) received the CSCI Joe Doupe Young Investigator Award. Over 60 abstracts were showcased, most of which are summarized in this review, and six were selected for oral presentations. Following the AJM, trainees participated in ICAM's three-day health research program, where three AJM attendees were recognized among the top four presenters and were invited to the 2024 Canada Gairdner Awards Gala, with one of our AJM attendees winning the competition and being named the next Lindau Nobel Laurate Meetings Nominee.

加拿大临床研究学会(CSCI)和加拿大临床研究员培训协会(CITAC) 2024年年度联席会议(AJM)和青年研究者论坛于2024年4月11日在不列颠哥伦比亚省温哥华举行。本次会议由英属哥伦比亚大学(UBC)和国际学术医学大会(ICAM)联合主办,为临床研究员实习生提供了一个重要的机会来展示他们的研究成果,并与国内和国际同行建立联系。该活动包括70名学员,包括58名MD+ (MD/PhD, MD和PhD, MD-MSc, MD和MSc)和12名临床研究员项目和/或外科科学家培训项目学员。主讲人Marco Marra博士发表了题为“从秀丽隐杆线虫遗传学到精确的癌症基因组医学,通过人类基因组计划:对合作科学之旅的反思”的演讲。Kenneth Rockwood博士(Dalhousie University)获得CSCI杰出科学家奖,Bertrand Routy博士(universit de montrachim)获得CSCI Joe Doupe青年研究者奖。60多篇摘要被展示,其中大部分在本综述中进行了总结,并选择了6篇进行口头报告。在AJM之后,学员们参加了ICAM为期三天的健康研究项目,其中三名AJM与会者被认可为前四名演讲者,并被邀请参加2024年加拿大盖尔德纳奖颁奖晚会,其中一名AJM与会者赢得了比赛,并被提名为下一届林道诺贝尔奖获得者会议提名人。
{"title":"Overview of the Canadian Clinician Investigator Trainees' Research Presented at the 2024 CSCI-CITAC Joint Meeting.","authors":"MohdWessam Al Jawhri, Salonee V Patel, Shubham Soni, Richard Huang, Robert X Lao","doi":"10.3138/CIM-47-4-REPORT","DOIUrl":"https://doi.org/10.3138/CIM-47-4-REPORT","url":null,"abstract":"<p><p>The 2024 Annual Joint Meeting (AJM) and Young Investigators' Forum of the Canadian Society for Clinical Investigation (CSCI) and Clinician Investigator Trainee Association of Canada (CITAC) was held on April 11, 2024, in Vancouver, British Columbia. Hosted in collaboration with the University of British Columbia (UBC) and the International Congress on Academic Medicine (ICAM), this meeting marked a significant opportunity for clinician investigator trainees to present their research and connect with national and international peers. The event included 70 trainees, consisting of 58 MD+ (MD/PhD, MD and PhD, MD-MSc, MD and MSc) and 12 Clinician Investigator Program and/or Surgeon-Scientist Training Program trainees. The keynote speaker, Dr. Marco Marra, delivered a presentation titled \"From <i>C. elegans</i> Genetics to Precision Cancer Genomic Medicine, via the Human Genome Project: Reflections on a Collaborative Scientific Journey.\" Dr. Kenneth Rockwood (Dalhousie University) received the CSCI Distinguished Scientist Award, and Dr. Bertrand Routy (Université de Montréal) received the CSCI Joe Doupe Young Investigator Award. Over 60 abstracts were showcased, most of which are summarized in this review, and six were selected for oral presentations. Following the AJM, trainees participated in ICAM's three-day health research program, where three AJM attendees were recognized among the top four presenters and were invited to the 2024 Canada Gairdner Awards Gala, with one of our AJM attendees winning the competition and being named the next Lindau Nobel Laurate Meetings Nominee.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":"47 4","pages":"3-10"},"PeriodicalIF":1.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CIM-CITAC Publication Award. CIM-CITAC出版物奖。
IF 1.2 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 DOI: 10.3138/CIM-47-4-AWARD
{"title":"CIM-CITAC Publication Award.","authors":"","doi":"10.3138/CIM-47-4-AWARD","DOIUrl":"https://doi.org/10.3138/CIM-47-4-AWARD","url":null,"abstract":"","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":"47 4","pages":"2"},"PeriodicalIF":1.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New CIM Editor-in-Chief. 新任CIM总编辑。
IF 1.2 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 DOI: 10.3138/CIM-47-4-ANNOUNCEMENT
{"title":"New CIM Editor-in-Chief.","authors":"","doi":"10.3138/CIM-47-4-ANNOUNCEMENT","DOIUrl":"https://doi.org/10.3138/CIM-47-4-ANNOUNCEMENT","url":null,"abstract":"","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":"47 4","pages":"1"},"PeriodicalIF":1.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of miR-34a on Endothelial Cell Viability and Apoptosis in Ischemic Stroke: Unraveling the MTHFR-Homocysteine Pathway. 缺血性中风中 miR-34a 对内皮细胞活力和凋亡的影响:揭秘 MTHFR-同型半胱氨酸通路
IF 1.2 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-09-01 Epub Date: 2024-08-27 DOI: 10.3138/cim-2024-2711
Lina Liang, Xueli Yi, Chunfang Wang, Li Su, Guijiang Wei

Introduction: Ischemic stroke (IS) is a global health concern, often tied to dyslipidemia and vascular endothelial dysfunction. MicroRNA-34a (miR-34a) was reported to be up-regulated in the blood samples of patients with IS, but the specific role of miR-34a and methylenetetrahydrofolate reductase (MTHFR) in IS remains to be elucidated.

Methods: We studied 143 subjects: 71 IS patients, and 72 healthy controls. Human umbilical vein endothelial cells (HUVECs) were cultured and transfected with a miR-34a mimic, inhibitor, or negative control. The miR-34a expression in serum and HUVECs was quantified via quantitative reverse transcription polymerase chain reaction (qRT-PCR). Viability and apoptosis of HUVECs were assessed using CCK-8 assay and flow cytometry. The expression levels of bcl-2, bax, cyt-c, cleaved caspase 3, MTHFR, and homocysteine were measured by Western blot or enzyme-linked immunosorbent assay (ELISA). The relationship between miR-34a and MTHFR was verified by luciferase reporter assay. The levels of MTHFR and homocysteine in serum were examined by ELISA.

Results: MiR-34a expression was increased in IS patients and inhibited viability of HUVECs while promoting their apoptosis. Overexpression of miR-34a up-regulated pro-apoptotic proteins (bax, cyt-c and cleaved caspase 3) and down-regulated anti-apoptotic protein bcl-2 in HUVECs. MTHFR was identified as the downstream target of miR-34a and its expression was reduced by miR-34a overexpression, while homocysteine levels increased. Consistently, MTHFR levels were lower and homocysteine levels were higher in IS patients compared with controls.

Discussion: Our results suggest that up-regulated miR-34a plays a role in the pathogenesis of IS, potentially through inhibiting MTHFR expression and increasing homocysteine in endothelial cells. Therefore, miR-34a might be a therapeutic target for IS.

导言:缺血性中风(IS)是全球关注的健康问题,通常与血脂异常和血管内皮功能障碍有关。据报道,缺血性中风患者血液样本中的微RNA-34a(miR-34a)被上调,但miR-34a和亚甲基四氢叶酸还原酶(MTHFR)在缺血性中风中的具体作用仍有待阐明:方法:我们对 143 名受试者进行了研究:方法:我们研究了 143 名受试者:71 名 IS 患者和 72 名健康对照组。培养人脐静脉内皮细胞(HUVECs),并用 miR-34a 模拟物、抑制剂或阴性对照组进行转染。通过定量反转录聚合酶链反应(qRT-PCR)对血清和 HUVEC 中 miR-34a 的表达进行了定量。使用 CCK-8 检测法和流式细胞术评估了 HUVEC 的活力和凋亡。通过 Western 印迹或酶联免疫吸附试验(ELISA)检测了 bcl-2、bax、cyt-c、裂解的 caspase 3、MTHFR 和同型半胱氨酸的表达水平。荧光素酶报告实验验证了 miR-34a 与 MTHFR 之间的关系。用酶联免疫吸附试验检测血清中 MTHFR 和同型半胱氨酸的水平:结果:IS 患者体内 MiR-34a 表达增加,抑制了 HUVECs 的活力,同时促进了其凋亡。过量表达 miR-34a 会上调促凋亡蛋白(bax、cyt-c 和裂解的 caspase 3),下调抗凋亡蛋白 bcl-2。MTHFR 被确定为 miR-34a 的下游靶标,miR-34a 过表达会降低其表达,而同型半胱氨酸水平则会升高。与对照组相比,IS 患者的 MTHFR 水平较低,而同型半胱氨酸水平较高:我们的研究结果表明,上调的 miR-34a 可能通过抑制 MTHFR 的表达和增加内皮细胞中的同型半胱氨酸,在 IS 的发病机制中发挥作用。因此,miR-34a可能是IS的治疗靶点。
{"title":"The Impact of miR-34a on Endothelial Cell Viability and Apoptosis in Ischemic Stroke: Unraveling the <i>MTHFR</i>-Homocysteine Pathway.","authors":"Lina Liang, Xueli Yi, Chunfang Wang, Li Su, Guijiang Wei","doi":"10.3138/cim-2024-2711","DOIUrl":"10.3138/cim-2024-2711","url":null,"abstract":"<p><strong>Introduction: </strong>Ischemic stroke (IS) is a global health concern, often tied to dyslipidemia and vascular endothelial dysfunction. MicroRNA-34a (miR-34a) was reported to be up-regulated in the blood samples of patients with IS, but the specific role of miR-34a and methylenetetrahydrofolate reductase (MTHFR) in IS remains to be elucidated.</p><p><strong>Methods: </strong>We studied 143 subjects: 71 IS patients, and 72 healthy controls. Human umbilical vein endothelial cells (HUVECs) were cultured and transfected with a miR-34a mimic, inhibitor, or negative control. The miR-34a expression in serum and HUVECs was quantified via quantitative reverse transcription polymerase chain reaction (qRT-PCR). Viability and apoptosis of HUVECs were assessed using CCK-8 assay and flow cytometry. The expression levels of bcl-2, bax, cyt-c, cleaved caspase 3, MTHFR, and homocysteine were measured by Western blot or enzyme-linked immunosorbent assay (ELISA). The relationship between miR-34a and MTHFR was verified by luciferase reporter assay. The levels of MTHFR and homocysteine in serum were examined by ELISA.</p><p><strong>Results: </strong>MiR-34a expression was increased in IS patients and inhibited viability of HUVECs while promoting their apoptosis. Overexpression of miR-34a up-regulated pro-apoptotic proteins (bax, cyt-c and cleaved caspase 3) and down-regulated anti-apoptotic protein bcl-2 in HUVECs. MTHFR was identified as the downstream target of miR-34a and its expression was reduced by miR-34a overexpression, while homocysteine levels increased. Consistently, MTHFR levels were lower and homocysteine levels were higher in IS patients compared with controls.</p><p><strong>Discussion: </strong>Our results suggest that up-regulated miR-34a plays a role in the pathogenesis of IS, potentially through inhibiting MTHFR expression and increasing homocysteine in endothelial cells. Therefore, miR-34a might be a therapeutic target for IS.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":"47 3","pages":"27-37"},"PeriodicalIF":1.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Newsletter Fall 2024: Clinician Investigator Trainee Association of Canada (CITAC). 2024 年秋季通讯:加拿大临床研究员受训者协会(CITAC)。
IF 1.2 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-09-01 DOI: 10.3138/cim-47-3-news
MohdWessam Al Jawhri, Salonee V Patel, Teija Bily, Yujin Suk, Robert X Lao
{"title":"Newsletter Fall 2024: Clinician Investigator Trainee Association of Canada (CITAC).","authors":"MohdWessam Al Jawhri, Salonee V Patel, Teija Bily, Yujin Suk, Robert X Lao","doi":"10.3138/cim-47-3-news","DOIUrl":"https://doi.org/10.3138/cim-47-3-news","url":null,"abstract":"","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":"47 3","pages":"1-4"},"PeriodicalIF":1.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Application of CT Imaging Grading System in Upper Urinary Tract Calculi with Kidney Infection. CT 成像分级系统在上尿路结石合并肾脏感染中的临床应用
IF 1.2 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-09-01 DOI: 10.3138/cim-2024-0107
Jianping Zhang, Lingfeng Zhu, Xiaoxia Wu, Haiying Chen, Runyang Pan, Zihuang Hong, Rongkai Lin

Purpose: This study aimed to establish a CT imaging grading system and explore its value in evaluating upper urinary tract calculi associated with kidney infections.

Methods: CT images of 126 patients with kidney infections caused by upper urinary tract calculi were retrospectively analyzed. The CT grading system was developed based on CT images. CT images were classified into 4 grades. General information, symptoms, and clinical findings of patients in different CT grades were analyzed. With the occurrence of systemic inflammatory response syndrome (SIRS) as the endpoint, univariate and multivariate analysis was conducted to analyze the risk factors of SIRS.

Results: Patients with fever or diabetes had higher CT grades, and the following examination data revealed significant differences across the various CT grades (P < 0.05): the white blood cell count, urine leucocytes count, CT1, CT2, maximum body temperature, duration of disease, the proportion of blood neutrophils, the size of stones, and levels of the C-reactive protein and procalcitonin. Only CT grading was statistically significant after multivariate analysis. According to the values of the partial regression coefficient (B), the higher the CT grade, the greater the risk of SIRS. The risk of SIRS was 4.472 times higher with each increment of the CT grade.

Conclusions: The CT grade is directly associated with clinical symptoms and the risk of SIRS.

目的:本研究旨在建立一套 CT 成像分级系统,并探讨其在评估与肾脏感染相关的上尿路结石方面的价值:方法:回顾性分析了126例由上尿路结石引起的肾脏感染患者的CT图像。根据 CT 图像建立了 CT 分级系统。CT 图像被分为 4 个等级。分析了不同 CT 分级患者的一般信息、症状和临床表现。以全身炎症反应综合征(SIRS)的发生率为终点,进行单变量和多变量分析,以分析SIRS的风险因素:发热或糖尿病患者的CT分级更高,以下检查数据在不同CT分级之间存在显著差异(P<0.05):白细胞计数、尿白细胞计数、CT1、CT2、最高体温、病程、血中性粒细胞比例、结石大小、C反应蛋白和降钙素原水平。经多变量分析,只有CT分级具有统计学意义。根据部分回归系数(B)的值,CT分级越高,发生SIRS的风险越大。CT分级每增加一级,SIRS的风险就增加4.472倍:结论:CT 分级与临床症状和 SIRS 风险直接相关。
{"title":"Clinical Application of CT Imaging Grading System in Upper Urinary Tract Calculi with Kidney Infection.","authors":"Jianping Zhang, Lingfeng Zhu, Xiaoxia Wu, Haiying Chen, Runyang Pan, Zihuang Hong, Rongkai Lin","doi":"10.3138/cim-2024-0107","DOIUrl":"https://doi.org/10.3138/cim-2024-0107","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to establish a CT imaging grading system and explore its value in evaluating upper urinary tract calculi associated with kidney infections.</p><p><strong>Methods: </strong>CT images of 126 patients with kidney infections caused by upper urinary tract calculi were retrospectively analyzed. The CT grading system was developed based on CT images. CT images were classified into 4 grades. General information, symptoms, and clinical findings of patients in different CT grades were analyzed. With the occurrence of systemic inflammatory response syndrome (SIRS) as the endpoint, univariate and multivariate analysis was conducted to analyze the risk factors of SIRS.</p><p><strong>Results: </strong>Patients with fever or diabetes had higher CT grades, and the following examination data revealed significant differences across the various CT grades (<i>P</i> < 0.05): the white blood cell count, urine leucocytes count, CT1, CT2, maximum body temperature, duration of disease, the proportion of blood neutrophils, the size of stones, and levels of the C-reactive protein and procalcitonin. Only CT grading was statistically significant after multivariate analysis. According to the values of the partial regression coefficient (B), the higher the CT grade, the greater the risk of SIRS. The risk of SIRS was 4.472 times higher with each increment of the CT grade.</p><p><strong>Conclusions: </strong>The CT grade is directly associated with clinical symptoms and the risk of SIRS.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":"47 3","pages":"7-17"},"PeriodicalIF":1.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Young Investigator Interview with CSCI Awardee, Dr. Kenneth Rockwood. 与 CSCI 获奖者 Kenneth Rockwood 博士的青年研究员访谈。
IF 1.2 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-09-01 DOI: 10.3138/cim-47-3-award
Salonee V Patel, Kenneth Rockwood

[Figure: see text] Dr. Kenneth Rockwood is a Professor of Medicine in the Division of Geriatric Medicine and Neurology and Clinical Research Professor of Frailty and Aging at Dalhousie University, as well as an actively practising geriatric physician. Dr. Rockwood has made significant contributions to geriatric medicine and research, including his involvement in developing the Clinical Frailty Scale. He has been recognized with countless prestigious awards, the most recent being the Distinguished Scientist Award from the Canadian Society for Clinical Investigation.

[图:见正文] 肯尼斯-罗克伍德博士是达尔豪斯大学老年医学和神经病学部医学教授、虚弱与衰老临床研究教授,同时也是一名积极执业的老年医学医生。洛克伍德博士对老年医学和研究做出了重大贡献,包括参与开发临床虚弱量表。他获得过无数著名奖项,最近的奖项是加拿大临床研究学会颁发的杰出科学家奖。
{"title":"Young Investigator Interview with CSCI Awardee, Dr. Kenneth Rockwood.","authors":"Salonee V Patel, Kenneth Rockwood","doi":"10.3138/cim-47-3-award","DOIUrl":"10.3138/cim-47-3-award","url":null,"abstract":"<p><p>[Figure: see text] Dr. Kenneth Rockwood is a Professor of Medicine in the Division of Geriatric Medicine and Neurology and Clinical Research Professor of Frailty and Aging at Dalhousie University, as well as an actively practising geriatric physician. Dr. Rockwood has made significant contributions to geriatric medicine and research, including his involvement in developing the Clinical Frailty Scale. He has been recognized with countless prestigious awards, the most recent being the Distinguished Scientist Award from the Canadian Society for Clinical Investigation.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":"47 3","pages":"5-6"},"PeriodicalIF":1.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global Trends and Frontier in Research on Pancreatic Alpha Cells: A Bibliometric Analysis from 2013 to 2023. 胰腺α细胞研究的全球趋势和前沿:2013年至2023年文献计量分析》。
IF 1.2 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-06-01 DOI: 10.3138/cim-2024-2744
Teng Guo, Haoling Zhang, Yunpeng Luo, Xi Yang, Lidan Wang, Guangde Zhang

Purpose: Over the past 20 years, much of the research on diabetes has focused on pancreatic beta cells. In the last 10 years, interest in the important role of pancreatic alpha cells in the pathogenesis of diabetes, which had previously received little attention, has grown. We aimed to summarize and visualize the hotspot and development trends of pancreatic alpha cells through bibliometric analysis and to provide research direction and future ideas for the treatment of diabetes and other islet-related diseases.

Methods: We used two scientometric software packages (CiteSpace 6.1.R6 and VOSviewer1.6.18) to visualize the information and connection of countries, institutions, authors, and keywords in this field.

Results: A total of 532 publications, published in 752 institutions in 46 countries and regions, were included in this analysis. The United States showed the highest output, accounting for 39.3% of the total number of published papers. The most active institution was Vanderbilt University, and the authors with highest productivity came from Ulster University. In recent years, research hotspots have concentrated on transdifferentiation, gene expression, and GLP-1 regulatory function. Visualization analysis shows that research hotspots mainly focus on clinical diseases as well as physiological and pathological mechanisms and related biochemical indicators.

Conclusions: This study provides a review and summary of the literature on pancreatic alpha cells through bibliometric and visual methods and shows research hotspot and development trends, which can guide future directions for research.

目的:在过去 20 年中,有关糖尿病的大部分研究都集中在胰腺 beta 细胞上。近 10 年来,人们对胰腺α细胞在糖尿病发病机制中的重要作用越来越感兴趣,而胰腺α细胞以前很少受到关注。我们的目的是通过文献计量学分析,总结胰岛α细胞的研究热点和发展趋势,为糖尿病及其他与胰岛相关疾病的治疗提供研究方向和未来思路:我们使用两个科学计量学软件包(CiteSpace 6.1.R6和VOSviewer1.6.18)对该领域的国家、机构、作者和关键词的信息和联系进行了可视化分析:本次分析共收录了 46 个国家和地区的 752 家机构发表的 532 篇论文。美国的论文数量最多,占发表论文总数的 39.3%。最活跃的机构是范德比尔特大学,产量最高的作者来自阿尔斯特大学。近年来,研究热点主要集中在转分化、基因表达和GLP-1调控功能等方面。可视化分析表明,研究热点主要集中在临床疾病以及生理病理机制和相关生化指标上:本研究通过文献计量学和可视化方法对胰腺α细胞的相关文献进行了回顾和总结,并展示了研究热点和发展趋势,为今后的研究方向提供了指导。
{"title":"Global Trends and Frontier in Research on Pancreatic Alpha Cells: A Bibliometric Analysis from 2013 to 2023.","authors":"Teng Guo, Haoling Zhang, Yunpeng Luo, Xi Yang, Lidan Wang, Guangde Zhang","doi":"10.3138/cim-2024-2744","DOIUrl":"https://doi.org/10.3138/cim-2024-2744","url":null,"abstract":"<p><strong>Purpose: </strong>Over the past 20 years, much of the research on diabetes has focused on pancreatic beta cells. In the last 10 years, interest in the important role of pancreatic alpha cells in the pathogenesis of diabetes, which had previously received little attention, has grown. We aimed to summarize and visualize the hotspot and development trends of pancreatic alpha cells through bibliometric analysis and to provide research direction and future ideas for the treatment of diabetes and other islet-related diseases.</p><p><strong>Methods: </strong>We used two scientometric software packages (CiteSpace 6.1.R6 and VOSviewer1.6.18) to visualize the information and connection of countries, institutions, authors, and keywords in this field.</p><p><strong>Results: </strong>A total of 532 publications, published in 752 institutions in 46 countries and regions, were included in this analysis. The United States showed the highest output, accounting for 39.3% of the total number of published papers. The most active institution was Vanderbilt University, and the authors with highest productivity came from Ulster University. In recent years, research hotspots have concentrated on transdifferentiation, gene expression, and GLP-1 regulatory function. Visualization analysis shows that research hotspots mainly focus on clinical diseases as well as physiological and pathological mechanisms and related biochemical indicators.</p><p><strong>Conclusions: </strong>This study provides a review and summary of the literature on pancreatic alpha cells through bibliometric and visual methods and shows research hotspot and development trends, which can guide future directions for research.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":"47 2","pages":"23-39"},"PeriodicalIF":1.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recommendations for Recovery of the COVID-19 Pandemic-related Diagnostic, Screening, and Procedure Backlog in Ontario: A Survey of Healthcare Leaders. 关于恢复安大略省 COVID-19 大流行相关诊断、筛查和手术积压的建议:医疗保健领导者调查。
IF 1.2 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-06-01 DOI: 10.3138/cim-2024-2655
Teagan T Telesnicki, Andrea N Simpson, Charles de Mestral, Nancy N Baxter, David R Urbach, David Gomez

Purpose: The COVID-19 pandemic has resulted in a significant diagnostic, screening, and procedure backlog in Ontario. Engagement of key stakeholders in healthcare leadership positions is urgently needed to inform a comprehensive provincial recovery strategy.

Methods: A list of 20 policy recommendations addressing the diagnostic, screening and procedure backlog in Ontario were transformed into a national online survey. Policy recommendations were rated on a 7-point Likert scale (strongly agree to strongly disagree) and organized into those retained (≥75% strongly agree to somewhat agree), discarded (≥80% somewhat disagree to strongly disagree), and no consensus reached. Survey participants included a diverse sample of healthcare leaders with the potential to impact policy reform.

Results: Of 56 healthcare leaders invited to participate, there were 34 unique responses (61% response rate). Participants were from diverse clinical backgrounds, including surgical subspecialties, medicine, nursing, and healthcare administration and held institutional or provincial leadership positions. A total of 11 of 20 policy recommendations reached the threshold for consensus agreement with the remaining 9 having no consensus reached.

Conclusion: Consensus agreement was reached among Canadian healthcare leaders on 11 policy recommendations to address the diagnostic, screening, and procedure backlog in Ontario. Recommendations included strategies to address patient information needs on expected wait times, expand health and human resource capacity, and streamline efficiencies to increase operating room output. No consensus was reached on the optimal funding strategy within the public system in Ontario or the appropriateness of implementing private funding models.

目的:COVID-19 大流行导致安大略省诊断、筛查和手术严重积压。迫切需要医疗保健领导岗位上的主要利益相关者参与进来,以便为全面的省级恢复战略提供信息:方法:将针对安大略省诊断、筛查和手术积压问题的 20 项政策建议清单转化为一项全国性在线调查。调查采用李克特 7 点量表(非常同意到非常不同意)对政策建议进行评分,并将其分为保留(≥75% 非常同意到比较同意)、放弃(≥80% 比较不同意到非常不同意)和未达成共识。调查参与者包括可能对政策改革产生影响的不同医疗保健领导者:在受邀参与调查的 56 位医疗保健领导者中,有 34 位做出了回复(回复率为 61%)。参与者来自不同的临床背景,包括外科亚专科、医学、护理和医疗保健管理,并担任机构或省级领导职务。在 20 项政策建议中,共有 11 项达到了达成共识的门槛,其余 9 项未达成共识:加拿大医疗保健领导人就 11 项政策建议达成了共识,以解决安大略省诊断、筛查和手术积压问题。建议包括解决患者对预期等待时间的信息需求、扩大卫生和人力资源能力、提高效率以增加手术室产出等策略。对于安大略省公共系统内的最佳筹资战略或实施私人筹资模式的适当性未达成共识。
{"title":"Recommendations for Recovery of the COVID-19 Pandemic-related Diagnostic, Screening, and Procedure Backlog in Ontario: A Survey of Healthcare Leaders.","authors":"Teagan T Telesnicki, Andrea N Simpson, Charles de Mestral, Nancy N Baxter, David R Urbach, David Gomez","doi":"10.3138/cim-2024-2655","DOIUrl":"https://doi.org/10.3138/cim-2024-2655","url":null,"abstract":"<p><strong>Purpose: </strong>The COVID-19 pandemic has resulted in a significant diagnostic, screening, and procedure backlog in Ontario. Engagement of key stakeholders in healthcare leadership positions is urgently needed to inform a comprehensive provincial recovery strategy.</p><p><strong>Methods: </strong>A list of 20 policy recommendations addressing the diagnostic, screening and procedure backlog in Ontario were transformed into a national online survey. Policy recommendations were rated on a 7-point Likert scale (strongly agree to strongly disagree) and organized into those retained (≥75% strongly agree to somewhat agree), discarded (≥80% somewhat disagree to strongly disagree), and no consensus reached. Survey participants included a diverse sample of healthcare leaders with the potential to impact policy reform.</p><p><strong>Results: </strong>Of 56 healthcare leaders invited to participate, there were 34 unique responses (61% response rate). Participants were from diverse clinical backgrounds, including surgical subspecialties, medicine, nursing, and healthcare administration and held institutional or provincial leadership positions. A total of 11 of 20 policy recommendations reached the threshold for consensus agreement with the remaining 9 having no consensus reached.</p><p><strong>Conclusion: </strong>Consensus agreement was reached among Canadian healthcare leaders on 11 policy recommendations to address the diagnostic, screening, and procedure backlog in Ontario. Recommendations included strategies to address patient information needs on expected wait times, expand health and human resource capacity, and streamline efficiencies to increase operating room output. No consensus was reached on the optimal funding strategy within the public system in Ontario or the appropriateness of implementing private funding models.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":"47 2","pages":"4-11"},"PeriodicalIF":1.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spring 2024: Clinician Investigator Trainee Association of Canada (CITAC). 2024 年春:加拿大临床研究员受训者协会(CITAC)。
IF 1.2 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-06-01 DOI: 10.3138/cim-2024-2740
MohdWessam Al Jawhri, Salonee V Patel, Robert X Lao
{"title":"Spring 2024: Clinician Investigator Trainee Association of Canada (CITAC).","authors":"MohdWessam Al Jawhri, Salonee V Patel, Robert X Lao","doi":"10.3138/cim-2024-2740","DOIUrl":"https://doi.org/10.3138/cim-2024-2740","url":null,"abstract":"","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":"47 2","pages":"1-3"},"PeriodicalIF":1.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical and Investigative Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1